BUZZ-Eli Lilly falls after report of delay in FDA decision on weight-loss pill

Reuters01-15
BUZZ-Eli Lilly falls after report of delay in FDA decision on weight-loss pill

** Eli Lilly LLY.N shares fall 1% to $1,062 premarket after Reuters reports U.S. FDA has delayed decision on company's weight-loss pill to April 10

** The decision was previously expected by late-March

** The drug was tapped for the administration's fast-track review program, which promised decisions in one or two months for a limited number of drugs deemed critical to public health or national security

** FDA also pushed reviews of Disc Medicine's IRON.O rare blood disorder drug and Sanofi's SASY.PA Tzield for type 1 diabetes after agency scientists flagged safety and efficacy concerns, report says

** LLY up 44% over the past year

(Reporting by Tharuniyaa Lakshmi in Bengaluru)

((tharuniyaa@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment